Incidence of acute phase reactions (APRs) in patients with advanced cancer or multiple myeloma (MM) And bone metastases/lesions following treatment with denosumab or zoledronic acid (ZA) — ASN Events
  1. Schedule
  2. COSA Posters: Translational Research
  3. Incidence of acute phase reactions (APRs) in patients with advanced cancer or multiple myeloma (MM) And bone metastases/lesions following treatment with denosumab or zoledronic acid (ZA)

Incidence of acute phase reactions (APRs) in patients with advanced cancer or multiple myeloma (MM) And bone metastases/lesions following treatment with denosumab or zoledronic acid (ZA) (#815)

Nina Singh RN 1 , Cynthia Campbell-Baird RN, OCN 2 , Hans Polderdijk RN 3 , Stacey Harrelson RN 4 , Judith Buechel RN 5 , Tap Maniar MD 6
  1. Sydney Haematology and Oncology Clinics Clinical Trials Unit, Sydney Adventist Hospital, Wahroonga, NSW, Australia
  2. Penn State Milton S. Hershey Medical Center, Hershey, PA, USA
  3. HagaZiekenhuis-Leyenburg, Den Haag, Netherlands
  4. Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA
  5. Haematology and Oncology, Innsbruck University Hospital, Inssbruck, Austria
  6. Amgen Inc., Thousand Oaks, CA, USA
Publish consent withheld